University of Melbourne forced to rehire professor Stephan Matthai who was sacked after ‘highly inappropriate' messages
University of Melbourne engineering professor Stephan Matthai was dismissed in December 2024 for a series of incidents in 2017 and 2018 in which he sent 'numerous intimate texts and emails' to a PhD student that he was supervising.
The student went on to tell Dr Matthai that she loved him, which he did not reciprocate, however, the intimate messaging continued.
The student later told another professor that she no longer wanted Dr Matthai as her supervisor and was reassigned without making a formal complaint.
In January 2024, she contacted the university and alleged that Dr Matthai had sexually harassed her.
The university investigated the matter and found there was no basis for the sexual harassment allegation, but Dr Matthai's messages were 'highly inappropriate'.
In one interaction, Dr Matthai and the student discussed body types, and he sent a photo of himself in boxers – at the time he said it was to demonstrate that he was an ectomorph or skinny person.
The student responded by asking: 'Can I love you German professor?'
Dr Matthai replied: 'You do not need my permission, do you?'
He told the university's external investigator that he sent the picture as he was feeling 'unworthy and abandoned' and needed some 'positive feedback'.
The University of Melbourne considered the behaviour to be serious misconduct and dismissed the professor.
While the Fair Work decision found that it was 'clear' that Dr Matthai's messages were inappropriate, it considered whether they were a valid reason for dismissal years after the offending.
'Nevertheless, I consider that it was harsh to dismiss Dr Matthai for misconduct that had occurred so long ago, in circumstances where he had maintained an unblemished record over the following seven years of his employment,' Deputy President Alan Colman found.
'In my view, the dismissal was unfair, and the appropriate remedy is for Dr Matthai to be reinstated.'
The commission found that while Dr Matthai was not pursuing a romantic relationship with the student, he was going through a 'difficult' break-up with his then partner and wanted his 'close relationship' with the student to continue.
'Not everyone is willing to listen to the sorrows of the broken-hearted,' Mr Colman wrote in his decision.
The university was instructed to reinstate Dr Matthai to his position immediately and pay him more than $28,000 for lost income during his period of dismissal.
The Fair Work Commission orders, handed down on Monday, July 7, made clear the reinstatement must happen within 14 days.
In a statement, the University of Melbourne said it was considering an appeal of the ruling, with a spokesperson saying the university was 'disappointed' in the decision.
'The university is considering its options to appeal the decision and will not comment further on this matter at this time,' they said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
40 minutes ago
- ABC News
Australia has a love-hate relationship with the ibis. But is the 'bin chicken' underrated?
Whether it's their weirdly bald head, rubbish-eating tendancies, or distinctive aroma, the ibis has become an easy target for scorn. But despite living near landfills and stealing the odd chip, they're not universally disliked. Or, at least, they're not disliked as much anymore. A growing number of people see them as misunderstood, loveable bin scamps that have cleverly adapted to a new, human-centric world. To find the nation's most beloved faunal underdog, ABC Science has just released a list of 10 underrated Australian animals to vote on. Eagle-eyed readers might notice the Australian white ibis — Threskiornis molucca, or the beloved "bin chicken" — is suspiciously absent. Ibis supporters may argue this is an urban-bird hit job. Others may suggest the smelly scavengers are too popular to compete. Because while the ibis is a polarising figure, Australia is spoiled for choice when it comes to underrated animals. There are thousands of contenders that don't get the recognition they deserve. First, it's worth understanding what underrated means. In this competition, we're looking for incredible native Australian critters that are largely unknown or under-appreciated. Dominique Potvin, a bird ecologist at the University of the Sunshine Coast who has spent years researching the Australian white ibis, argues the ibis is not underrated. "They're polarising … whether you love it or hate it, I don't think you can underrate it." Now, Dr Potvin is no ibis hater. She proudly displays her ibis earrings while being interviewed. In fact, the ecologist is partly responsible for the ibis's reputation renovation. Her team's work, which encouraged citizen scientists to use the Big City Birds app to name and follow hundreds of tagged birds, has even made some people warm to the creatures. "They started thinking 'Oh there's my ibis, Jack' or 'Oh my gosh, that one went to Bunnings on a Sunday and got a sausage.' "They would start to get to know them and gained that sense of connection." That's not the case for many other animals, and that can make them more vulnerable to becoming extinct. Some of Australia's highly under-appreciated animals actually live on the skin of the ibis, hidden under its feathers. "I've been part of a paper that described a louse species on ibis," Dr Potvin says. Understanding why humans care more about the ibis than the lice living on them is worth investigating, according to Kate Umbers, a entomologist at the University of Western Sydney. "Some of the most threatened species are the parasites of the species we love. So parasites of giant pandas, parasites of koalas," she says. "There's a real value judgement there around what is important, what deserves to live, and what deserves to go extinct." Dr Umbers is the director of Invertebrates Australia, and is passionate about highlighting the creatures most likely to fly under the radar: insects, molluscs, sponges, and other creatures without a backbone. "For me, the underrated species are the ones that we see every day, that we dismiss as uninteresting." That also means they're easy to overlook. "The estimates are that around two-thirds of the invertebrates in Australia haven't been described, and that equates to probably around 200,000 species," she says. And this lack of knowledge means that species could be going extinct, without anyone ever having known it existed. "Estimates recently suggested 9,000 invertebrates have gone extinct in Australia since colonisation, and that equates to still one to two per week going extinct," she says. "Some of those might have names, but by and large they probably don't." To get a species described and named, scientists need to include comparisons to other species, undertake DNA testing and much more, according to Dr Umbers. "Describing species is a whole science in itself, and it's often quite a lot of work," she said. Even once species have been described and named, that's not the end of the battle according to Meg Shaw, an environmental behaviour researcher at Monash University. Animals such as insects, frogs and reptiles simply are less common in our collective consciousness, which can then mean they get fewer resources to help save them. "With legislation, research funding, social media representation, and film and TV, we see a lot more mammals and birds than anything else," Dr Shaw says. But her recent research into wildlife photos and conservation organisations on social media suggests that reversing this trend might be as simple as selecting a wider variety of animals to highlight. "We found that although social media is swamped by photos of mammals and birds, when you looked at the level of engagement that these images were getting, there wasn't much difference between mammals, birds, amphibians, reptiles and invertebrates. "Just sharing more content about these under-represented species so that people recognise that they exist … is really important to get people aware, and then start raising that that level of empathy for them." We'd love to highlight all of Australia's underrated animals but we could only choose 10 for National Science Week. Will something furry like the marsupial mole, or slimy like the short-fin eel win? Does the palm cockatoo rock or is the desert skink the true underdog? Find out about each of the contenders or vote right now: Still can't decide? Listen to our special mini episodes on What the Duck?! The winner will be revealed on 15 August.
SBS Australia
an hour ago
- SBS Australia
Great Barrier Reef suffers sharp decline in coral coverage after 'unheard of' heat events
The latest survey from The Australian Institute of Marine Science shows coral cover on parts of the Great Barrier Reef has reduced by as much as a third from record high levels following a global mass bleaching event. The heat-vulnerable tropical ecosystem off the coast of Queensland has experienced its sharpest decline in hard coral prevalence in four decades, with a 2024 spike in ocean temperatures largely to blame. The survey does not capture the most recent bleaching event confirmed earlier in 2025 that struck the Great Barrier Reef as well as ecosystems off the Western Australian coastline. The growing prevalence of bleaching events Report co-author Dr Daniela Ceccarelli was concerned about the growing prevalence of bleaching events. "These back-to-back events were previously completely unheard of," Ceccarelli said. Heat stress events in quick succession were worrying given the emerging dominance of "fast to grow and first to go" Acropora coral species. Capable of bouncing back quickly after a destructive event when given more space to expand, the fast-growing varieties were largely responsible for the previous survey's record-high coral coverage rates. Ceccarelli likened the fast-growing corals to grasses and bushes that shoot up first after a bushfire. "And if you were to fly over, you'd go 'it's nice and green, it's great'," she explained. "But the trees are not there yet." Marine experts fear corals may not adapt to and recover from the impacts of climate change. Source: AAP / AAPIMAGE Heat stress threatening coral recovery With heat stress events coming too often for hardier, slow-growing corals to get a foothold, Ceccarelli warned such cycles of crash and rapid recovery were becoming more common. "The question is, how long can this go on before we reach a low from which recovery is not possible? "We don't know that, but it's worrying we aren't getting a lot of time between heatwaves anymore." Particularly sensitive to heat stress, corals expel the algae living in their tissues when water is too warm, causing the coral to turn completely white. Coral can recover from bleaching but it is a sign of stress and can kill the organisms if severe enough. Cyclones and crown-of-thorn starfish outbreaks also contribute to reef damage, but AIMS said climate change-fuelled ocean warming drove much of the 2024 coral coverage decline. Marine experts say coral can recover from bleaching but it can be fatal if severe enough Credit: AAPIMAGE Fears over further decline in reef health The entire tropical ecosystem recorded falls in coral coverage — an internationally-recognised indicator of reef health — but declines were sharpest in the south. Coverage fell by nearly a third in the southern region, from 38.9 per cent to 26.9 per cent. North of Cooktown, coverage fell by roughly a quarter. In the central region, hard corals shrunk nearly 14 per cent. Even with those sharp declines, when coming from such a high base, overall coverage is now hovering around long-run averages. AIMS chief executive officer Selina Stead said ocean warming caused by climate change was clearly impacting coral reefs. "The future of the world's coral reefs relies on strong greenhouse gas emissions reduction, management of local and regional pressures, and development of approaches to help reefs adapt to and recover from the impacts of climate," Stead said.
News.com.au
2 hours ago
- News.com.au
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.
